FOLFIRINOX + cetuximab + panitumumab

FOLFIRINOX + cetuximab + panitumumab is an investigational combination regimen that merges the multi-agent chemotherapy protocol FOLFIRINOX with two monoclonal antibodies, cetuximab and panitumumab. - **FOLFIRINOX** consists of four drugs: - folinic acid (leucovorin), which enhances the effects of fluorouracil, - fluorouracil (5-FU), a pyrimidine analog antimetabolite that inhibits DNA synthesis, - irinotecan, a topoisomerase I inhibitor preventing DNA replication, - oxaliplatin, a platinum-based agent disrupting DNA repair and synthesis[4][6]. - **Cetuximab** is an IgG1 chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling. - **Panitumumab** is a fully human IgG2 monoclonal antibody also targeting EGFR, inhibiting its activation. This combination aims to leverage both cytotoxic chemotherapy and targeted inhibition of EGFR signaling pathways. It has been explored in clinical trials for advanced gastrointestinal cancers but is not standard therapy for any indication.